New Peer-Reviewed Paper on MiCheck® Prostate

New Peer-Reviewed Paper on MiCheck® Prostate

Minomic is pleased to announce the publication of the company’s latest research paper supporting the utilisation of MiCheck® Prostate as an aid to diagnosing clinically significant prostate cancer. It is clear there is strong clinical need to identify those patients...
Minomic’s participation at the AUA 2023

Minomic’s participation at the AUA 2023

The Minomic International Ltd team was delighted to share our new findings on the application of MiCheck® Prostate with MRI-derived data at the poster presentation session at the American Urological Association’s 2023 Annual Meeting on April 28 2023 in Chicago....
Minomic joins Macquarie University at the DeepTech Incubator

Minomic joins Macquarie University at the DeepTech Incubator

We are pleased to announce that Minomic International Ltd has officially joined Macquarie University at the DeepTech Incubator. “We are excited to continue our partnership with the Macquarie University Incubator, working with them to continue growing Minomic to its...
Minomic shared journey in the US market with 360Dx

Minomic shared journey in the US market with 360Dx

We had the opportunity to share Minomic’s journey from genesis of the company to launch of MiCheck® Prostate in the US market with 360Dx, a leading media outlet for the diagnostics industry. CEO of Minomic, Dr Brad Walsh, highlighted the clinical utility of this...